- Home
- LYEL
as 09-12-2025 4:00pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 207.7M | IPO Year: | 2021 |
| Target Price: | $15.00 | AVG Volume (30 days): | 25.5K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.65 - $32.00 | Next Earning Date: | 11-06-2025 |
| Revenue: | $60,000 | Revenue Growth: | 11.11% |
| Revenue Growth (this year): | -82.16% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hill Stephen J. | LYEL | Chief Operating Officer | Aug 21 '25 | Sell | $10.54 | 1,004 | $10,586.18 | 15,845 | |
| Seely Lynn | LYEL | President and CEO | Aug 21 '25 | Sell | $10.54 | 7,257 | $76,517.81 | 67,571 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Aug 21 '25 | Sell | $10.54 | 1,453 | $15,320.43 | 15,504 | |
| Newton Charles W. | LYEL | Chief Financial Officer | Aug 21 '25 | Sell | $10.54 | 1,453 | $15,320.43 | 15,306 | |
| Hill Stephen J. | LYEL | Chief Operating Officer | Aug 12 '25 | Sell | $10.34 | 94 | $971.77 | 15,845 | |
| Seely Lynn | LYEL | President and CEO | Aug 12 '25 | Sell | $10.34 | 406 | $4,197.23 | 67,571 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Aug 12 '25 | Sell | $10.34 | 136 | $1,405.97 | 15,504 | |
| Newton Charles W. | LYEL | Chief Financial Officer | Aug 12 '25 | Sell | $10.34 | 136 | $1,405.97 | 15,306 | |
| Hill Stephen J. | LYEL | Chief Operating Officer | Aug 11 '25 | Sell | $10.53 | 91 | $957.87 | 15,845 | |
| Seely Lynn | LYEL | President and CEO | Aug 11 '25 | Sell | $10.53 | 391 | $4,115.67 | 67,571 |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Clinical Trials Arena
3 months ago
Lyell reports new clinical data from trial of large B-cell lymphoma therapy
MT Newswires
3 months ago
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial
GlobeNewswire
3 months ago
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewswire
3 months ago
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
GlobeNewswire
3 months ago
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Associated Press Finance
4 months ago
Lyell Immunopharma: Q1 Earnings Snapshot
GlobeNewswire
4 months ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.